Coming October 29: SITC releases its late-breaking abstract titles. We’ll add their presenting authors’ institutions to this guide once they’re out.

Jecho Labs at SITC 2026

Nov 4–8, 2026 Phoenix, AZ ~6k attendees Website

Jecho Labs brings 2 presentations to SITC 2026 in Phoenix. Its program centres on new protein drugs for cancer immunotherapy, from lab testing to first trials in patients. The most concrete is a fusion protein steered to PD-L1 that carries the 4-1BB ligand and shows anti-tumor activity and good safety in preclinical models.

Organization	SITC 2026 Attendance
Jecho Labs Frederick, MD
jecholabs.com Biotech Biotechnology company developing therapeutic biologics, including cancer immunotherapies, and biopharmaceutical manufacturing processes.	Poster Fri Nov 6 12:15–1:45pm 5:30–7pm A novel PD-L1-directed 4-1BB ligand fusion protein, JLM070, demonstrates potent antitumor activity and a favorable safety profile in preclinical models Exhibition Halls 4-6 · Poster 927 New agents Poster Sat Nov 7 12:30–1:30pm 6:40–8:10pm A Phase I Study to Evaluate the Safety and Tolerability of JLM019 Injection in patients with advanced malignancies Exhibition Halls 4-6 · Poster 564 Clinical · New agents

Organization

SITC 2026 Attendance

Jecho Labs

Frederick, MD

jecholabs.com

Biotech

Biotechnology company developing therapeutic biologics, including cancer immunotherapies, and biopharmaceutical manufacturing processes.

Poster

Fri Nov 6
12:15–1:45pm
5:30–7pm

A novel PD-L1-directed 4-1BB ligand fusion protein, JLM070, demonstrates potent antitumor activity and a favorable safety profile in preclinical models

Exhibition Halls 4-6 · Poster 927

New agents